Republic of Korea-based biopharma company Celltrion is looking to accelerate its momentum in Europe; analysts belive that the company could receive the European Medicines Agency’s (EMA) approval to market its biosimilar of Roche’s blockbuster cancer treatment, Herceptin (trastuzumab), by March 2018.
Republic of Korea-based biopharma company Celltrion is looking to accelerate its momentum in Europe; according to The Investor, analysts believe that the company could receive the European Medicines Agency’s (EMA) approval to market its biosimilar of Roche’s blockbuster cancer treatment, Herceptin (trastuzumab), by March 2018.
Celltrion’s proposed trastuzumab biosimilar is the company’s third biosimilar product pursuing access to the European market, following the launch of Remsima, an infliximab biosimilar of Johnson & Johnson’s reference Remicade, and a rituximab biosimilar, Truxima, referenced on Rituxan.
“Herzuma will be well positioned for Celltrion to have confidence in sales based on 4 years of market experience (in Europe) and a strong partner network,” Park Si-hyeong, an analyst at IBK Securities, told The Investor.
Most recently, the FDA approved Mylan and Biocon's trastuzumab biosimilar, Ogivri. Other Herceptin products in development for the US and EU markets include:
In addition to its trastuzumab biosimilar, Celltrion is developing several other notable products:
The Investor reports that an official at Celltrion has indicated that Herzuma will be able to hit the European market 3 months after approval. Celltrion has not decided yet on its marketing partner for the drug, but it is likely to continue to work with existing partners such as Mundipharma, Biogaran, and Kern Pharma.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.